ISIS Pharmaceuticals (NASDAQ:ISIS) CEO Stanley T. Crooke sold 16,000 shares of ISIS Pharmaceuticals stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $30.53, for a total transaction of $488,480.00. Following the completion of the sale, the chief executive officer now directly owns 6,941 shares of the company’s stock, valued at approximately $211,909. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Shares of ISIS Pharmaceuticals (NASDAQ:ISIS) opened at 30.40 on Friday. ISIS Pharmaceuticals has a 52-week low of $22.25 and a 52-week high of $62.66. The stock has a 50-day moving average of $32.45 and a 200-day moving average of $38.23. The company’s market cap is $3.574 billion.
ISIS Pharmaceuticals (NASDAQ:ISIS) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.04. The company had revenue of $28.20 million for the quarter, compared to the consensus estimate of $35.12 million. During the same quarter in the previous year, the company posted ($0.02) earnings per share. The company’s revenue for the quarter was down 35.0% on a year-over-year basis. On average, analysts predict that ISIS Pharmaceuticals will post $-0.71 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on ISIS shares. Analysts at Zacks reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Thursday, June 5th. They now have a $29.00 price target on the stock. Separately, analysts at Summer Street reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Friday, May 23rd. Finally, analysts at TheStreet downgraded shares of ISIS Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 8th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $41.10.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.